Real-World Outcomes Among Patients With Early Rapidly Progressive Rheumatoid Arthritis
September 24th 2019This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.
Read More
2 Clarke Drive
Cranbury, NJ 08512